Cellivia

Cellivia is an early-stage biotech firm positioned at the intersection of biotechnology, medicine, and robotics, focusing on regenerative medicine. Its core business is banking oral tissues and cells, which are rich sources of mesenchymal stem cells (MSCs) with high regenerative potential, for future therapeutic use. The company targets a B2B2C model, partnering with dental clinics to collect materials and offering individuals a long-term health security service. While currently a service-based biobank, Cellivia is engaged in R&D to develop advanced therapy medicinal products (ATMPs) from its banked cells.

Platform for the collection, processing, and cryogenic banking of oral tissue-derived mesenchymal stem cells (MSCs) from dental pulp and gums, intended as a source for future personalized advanced therapies.

Cellivia competes in the niche of dental stem cell banking, which is less crowded than cord blood banking. However, it faces competition from other biobanks that may offer similar services and, in the long term, from alternative cell sourcing technologies (e.g., iPSCs). Its key competitive advantage is its early-mover focus in Poland and integrated network of dental clinics.